https://www.fool.com/investing/general/2011/01/05/five-technology-trends-to-watch-in-2011.aspx
https://www.fool.com/investing/general/2011/04/23/amazons-cloud-failure-reveals-shortsightedness-by-.aspx
https://www.fool.com/investing/general/2010/10/04/qualcomm-reportedly-moving-to-close-flo-tv-operati.aspx
https://www.fool.com/investing/general/2010/09/17/intel-and-the-three-ds-of-the-app-store-business.aspx
https://www.fool.com/investing/general/2011/07/14/seattle-genetics-wins-unanimous-ok-for-lymphoma-dr.aspx
https://www.fool.com/investing/general/2011/04/05/as-google-retools-its-search-engine-content-farms-.aspx
https://www.fool.com/investing/general/2011/04/21/ebays-acquisition-of-where-could-drive-paypals-mob.aspx
https://www.fool.com/investing/general/2010/11/16/dendreon-prepares-to-take-some-heat-over-cancer-dr.aspx
https://www.fool.com/investing/general/2011/09/21/orexigen-revives-obesity-drug-after-one-more-go-ro.aspx
https://www.fool.com/investing/general/2011/03/25/consumer-surplus-from-personal-technology-is-soari.aspx
https://www.fool.com/investing/high-growth/2010/10/22/aastrom-maps-out-pivotal-trial-strategy-with-adult.aspx
https://www.fool.com/investing/high-growth/2010/10/04/sanofi-aventis-launches-hostile-takeover-bid-for-g.aspx
https://www.fool.com/investing/general/2011/12/20/amgen-watson-strike-400m-deal-for-biosimilar-cance.aspx
https://www.fool.com/investing/general/2011/04/09/evolve-or-die-4-ways-med-device-companies-can-surv.aspx
https://www.fool.com/investing/general/2010/10/08/bristol-myers-almost-ready-to-seal-the-deal-with-z.aspx
https://www.fool.com/investing/general/2011/11/04/celgene-to-pump-45m-into-quanticel-to-discover-can.aspx
https://www.fool.com/investing/general/2011/12/24/beyond-the-tablet-wars-apple-amazon-and-the-cloud.aspx
https://www.fool.com/investing/general/2011/12/15/vertex-names-jeff-leiden-as-new-ceo-staring-down-t.aspx
https://www.fool.com/investing/general/2011/05/14/xerox-says-old-apple-legend-misses-the-point.aspx
https://www.fool.com/investing/high-growth/2010/10/08/onyx-delays-cancer-drug-application-as-fda-asks-fo.aspx
https://www.fool.com/investing/general/2011/05/27/yes-technology-is-taking-jobs-away-but-heres-how-i.aspx
https://www.fool.com/investing/general/2010/12/08/googles-news-e-books-and-android-and-chrome-oh-my.aspx
https://www.fool.com/investing/general/2011/09/28/why-amazons-tablet-matters-its-not-a-computer-its-.aspx
https://www.fool.com/investing/general/2011/07/01/mobile-apps-are-not-just-for-smartphones-ford-cour.aspx
https://www.fool.com/investing/general/2011/04/21/amgen-passes-key-trial-with-son-of-dmab-for-osteop.aspx
https://www.fool.com/investing/general/2011/08/08/dendreon-wounds-are-self-inflicted-not-the-start-o.aspx
https://www.fool.com/investing/general/2011/10/06/how-steve-jobs-rewired-our-lives-and-raised-our-ex.aspx
https://www.fool.com/investing/general/2011/07/08/amylin-alkermes-once-weekly-diabetes-drug-passes-h.aspx
https://www.fool.com/investing/general/2011/08/06/an-open-letter-to-dendreons-chairman.aspx
https://www.fool.com/investing/general/2011/09/08/bristol-pfizer-team-on-alert-as-fda-reviews-stroke.aspx
https://www.fool.com/investing/general/2010/12/14/inkling-reinvents-textbooks-for-the-ipad.aspx
https://www.fool.com/investing/general/2010/12/15/streaming-music-for-apple-itunes-users-courtesy-of.aspx
https://www.fool.com/investing/general/2011/08/18/are-free-motorola-phones-in-our-future-a-vcs-take-.aspx
https://www.fool.com/investing/general/2010/12/07/google-amazon-play-catch-up-in-group-buying.aspx
https://www.fool.com/investing/general/2010/09/18/clouds-in-sunny-san-diego-for-motorola-official.aspx
https://www.fool.com/investing/general/2011/02/22/gilead-buys-calistoga-pharma-making-move-into-canc.aspx
https://www.fool.com/investing/general/2011/10/11/agios-and-celgene-anatomy-of-an-ultra-valuable-bio.aspx
https://www.fool.com/investing/general/2011/01/07/here-are-6-features-apple-should-include-in-the-ip.aspx
https://www.fool.com/investing/general/2011/04/21/please-dont-go-microsoft-boosting-pay-across-compa.aspx
https://www.fool.com/investing/general/2011/02/07/sidereel-your-dial-tone-for-tv.aspx
https://www.fool.com/investing/general/2011/07/01/dendreon-sways-medicare-to-pay-for-prostate-cancer.aspx
https://www.fool.com/investing/general/2011/01/07/the-ipad-and-rich-media-apps-capitalizing-on-the-f.aspx
https://www.fool.com/investing/general/2011/11/10/amazon-pushing-national-sales-tax-bill.aspx
https://www.fool.com/investing/general/2011/05/13/the-ipad-finally-has-a-worthy-rival-samsungs-galax.aspx
https://www.fool.com/investing/general/2011/07/05/seattle-genetics-on-the-verge-of-going-commercial-.aspx
https://www.fool.com/investing/general/2011/11/19/regeneron-wins-fda-approval-for-macular-degenerati.aspx
https://www.fool.com/investing/general/2011/03/03/with-sanofi-buyout-of-genzyme-rare-disease-execs-u.aspx
https://www.fool.com/investing/general/2011/08/16/qualcomms-snaptracs-not-snaptrack-offers-new-pet-t.aspx
https://www.fool.com/investing/general/2011/02/03/boston-scientific-wants-to-be-a-rock-star-but-firs.aspx
https://www.fool.com/investing/general/2011/05/10/akamai-riverbed-team-up-to-speed-cloud-application.aspx
https://www.fool.com/investing/general/2010/09/17/cell-therapeutics-okd-to-sell-shares-to-stay-alive.aspx
https://www.fool.com/investing/general/2010/11/08/emcs-acquisition-strategy-new-insights-from-data-d.aspx
https://www.fool.com/investing/general/2011/10/05/merck-fine-tunes-biosimilars-strategy-as-fda-guide.aspx
https://www.fool.com/investing/general/2010/11/16/anthera-seeks-to-tap-heart-attack-market-by-blocki.aspx
https://www.fool.com/investing/general/2011/12/08/affymax-passes-fda-panel-scrutiny-looks-to-challen.aspx
https://www.fool.com/investing/general/2011/08/20/why-all-the-churn-around-clearwire.aspx
https://www.fool.com/investing/high-growth/2011/04/14/acorda-stock-halted-as-shares-skyrocket-on-patent-.aspx
https://www.fool.com/investing/general/2011/05/07/all-things-connected-qualcomm-executives-talk-abou.aspx
https://www.fool.com/investing/general/2011/04/13/ford-chasing-nissan-and-chevy-rolling-out-focus-ev.aspx
https://www.fool.com/investing/general/2011/07/12/seattle-genetics-new-empowered-antibody-looks-clea.aspx
https://www.fool.com/investing/general/2011/07/22/bristol-myers-acquires-amira-pharmaceuticals-scoop.aspx
https://www.fool.com/investing/general/2011/06/28/lost-in-translation-ford-teams-with-nuance-communi.aspx
https://www.fool.com/investing/general/2011/06/30/ibm-is-looking-to-buy-is-emc-in-its-crosshairs.aspx
https://www.fool.com/investing/general/2011/04/08/how-to-hire-and-fire-establish-company-culture-and.aspx
https://www.fool.com/investing/general/2010/12/16/microsoft-and-sentillion-a-progress-report-on-a-cr.aspx
https://www.fool.com/investing/general/2011/11/22/pfizer-acquires-excaliard-an-isis-spinout-with-dru.aspx
https://www.fool.com/investing/general/2011/02/09/amgen-pushes-ahead-with-son-of-dmab-for-treating-b.aspx
https://www.fool.com/investing/general/2010/11/15/emc-acquires-isilon-systems-now-the-real-work-begi.aspx
https://www.fool.com/investing/general/2011/04/26/fda-says-vertex-drug-a-wee-bit-more-effective-than.aspx
https://www.fool.com/investing/general/2011/06/06/exelixis-zeroes-in-on-lead-drug-sees-activity-in-t.aspx
https://www.fool.com/investing/general/2011/04/23/zillows-ipo-bellwether-of-a-new-boom.aspx
https://www.fool.com/investing/dividends-income/2011/01/28/merck-staring-at-a-biotech-future-seeks-to-get-in-.aspx
https://www.fool.com/investing/general/2011/02/22/forest-labs-snaps-up-clinical-data.aspx
https://www.fool.com/investing/general/2011/07/12/northrop-grumman-leads-15m-round-for-daylight-solu.aspx
https://www.fool.com/investing/general/2011/04/09/google-and-ita-software-the-acquisition-that-almos.aspx
https://www.fool.com/investing/general/2011/05/20/miller-tabak-fund-manager-says-investors-are-ignor.aspx
https://www.fool.com/investing/general/2011/01/21/searching-for-meaning-in-googles-leadership-change.aspx
https://www.fool.com/investing/general/2011/06/04/dear-apple-go-big-with-siri-and-nuance-in-ios-5.aspx
https://www.fool.com/investing/general/2011/03/21/t-mobiles-sale-to-att-what-theyre-saying-what-it-m.aspx
https://www.fool.com/investing/general/2011/04/21/5-questions-for-ibm-on-watson-jeopardy-and-real-wo.aspx
https://www.fool.com/investing/general/2011/01/21/the-age-of-tablet-superbooks-not-yet.aspx
https://www.fool.com/investing/general/2011/07/20/from-dominos-to-compuware-michigan-sees-its-future.aspx
https://www.fool.com/investing/general/2011/06/20/pfizers-idea-to-fix-the-drug-development-crisis-wh.aspx
https://www.fool.com/investing/general/2011/12/14/zillow-shows-why-microsoft-might-love-the-kindle-f.aspx
https://www.fool.com/investing/general/2010/09/29/amazons-top-techie-werner-vogels-on-how-web-servic.aspx
https://www.fool.com/investing/general/2011/12/20/att-drops-t-mobile-bid-will-pay-4b-breakup-fee.aspx
https://www.fool.com/investing/general/2011/04/02/dendreon-faces-internet-fueled-shareholder-uprisin.aspx
https://www.fool.com/investing/general/2011/08/26/steve-jobs-calling-the-stuff-of-customer-service-l.aspx
https://www.fool.com/investing/general/2011/05/27/forget-the-iphone-your-car-is-the-ultimate-mobile-.aspx
https://www.fool.com/investing/general/2011/08/20/seattle-genetics-wins-fda-approval-of-first-drug.aspx
https://www.fool.com/investing/general/2010/09/16/what-we-can-learn-from-the-flight-of-microsoft-exe.aspx
https://www.fool.com/investing/general/2011/06/02/infinity-dares-to-think-big-against-pancreatic-can.aspx
https://www.fool.com/investing/general/2011/10/08/sprint-makes-it-pretty-clear-clearwires-on-its-own.aspx
https://www.fool.com/investing/general/2011/04/15/amylin-alkermes-shares-jump-as-eu-regulators-recom.aspx
https://www.fool.com/investing/general/2011/06/03/orexigen-facing-high-hurdle-at-fda-puts-obesity-dr.aspx
https://www.fool.com/investing/general/2011/12/20/what-now-reactions-questions-after-the-att-mo-fail.aspx
https://www.fool.com/investing/general/2011/09/24/what-the-changes-at-facebook-mean-for-apple-and-go.aspx
https://www.fool.com/investing/general/2011/04/25/vertex-merck-step-up-to-the-public-stage-with-hepa.aspx
https://www.fool.com/investing/general/2011/05/17/merck-genentech-team-up-on-hepatitis-c-drug.aspx
https://www.fool.com/investing/general/2011/06/11/reports-say-google-wants-to-buy-admeld.aspx
